Evaluation of the Long Term Efficacy of Endovascular Treatment of Type 2 Endoleaks
1 other identifier
observational
19
1 country
1
Brief Summary
Endovascular treatment has become the first choice to repair abdominal aortic aneurym, but exposes patients to a risk of endoleaks. Although treatment of type 1 and 3 endoleaks has proven to prevent aneurysms from rupture, controversies remain about type 2 endoleaks. The investigators described the different techniques of type 2 endovascular repair, and their efficacy at short and long term..
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jan 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2020
CompletedFirst Submitted
Initial submission to the registry
May 26, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 26, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
May 26, 2020
CompletedFirst Posted
Study publicly available on registry
June 1, 2020
CompletedJune 1, 2020
May 1, 2020
5 months
May 26, 2020
May 29, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Recurrence rate of type II endoleaks treated with endovascular intervention
12 years
Secondary Outcomes (1)
Type of type II endoleaks treatment
12 years
Study Arms (1)
Patients treated for type II endoleaks
Patients treated for type II endoleaks between the 01 January 2008 and the 31 March 2018 in the Cardiovascular and Thoracic Surgery Unit of Dijon Burgundy University Hospital
Interventions
Type II endoleak endovascular treatment
Eligibility Criteria
All patients treated for type II endoleaks by endovascular therapy between the 01 January 2008 and the 31 December 2018
You may qualify if:
- All patients treated for type II endoleaks by endovascular therapy
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Cardiovascular and thoracic surgery unit, CHU Dijon
Dijon, 21079, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Eric STEINMETZ, MD
Cardiovascular and Thoracic Surgery Unit - Dijon Univeristy Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
May 26, 2020
First Posted
June 1, 2020
Study Start
January 1, 2020
Primary Completion
May 26, 2020
Study Completion
May 26, 2020
Last Updated
June 1, 2020
Record last verified: 2020-05
Data Sharing
- IPD Sharing
- Will not share
All patients signed a institutional form prior to the procedure stating that they did not object to the use of their medical data for research purposes. Before inclusion, all patients (or a trusted person) were informed about the study and its objectives. No opposition was expressed.